- Conditions
- Lymphoma
- Interventions
- Pegylated interferon α-2b, Psoralens with ultraviolet light A, Narrowband-ultraviolet light B
- Biological · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 32
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hematologic Malignancies
- Interventions
- extracorporeal photopheresis, Pentostatin, Total Body Irradiation
- Procedure · Drug · Radiation
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Boston, Massachusetts • San Antonio, Texas
- Conditions
- Crohn's Disease
- Interventions
- Methoxsalen +ECP, Extracorporeal Photopheresis
- Drug · Procedure
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 4
- States / cities
- Bethesda, Maryland • Chevy Chase, Maryland • Morristown, New Jersey + 1 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Extracorporeal Photochemotherapy With Transimmunization
- Procedure
- Lead sponsor
- Atlantic Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Morristown, New Jersey
- Conditions
- Immune-related Colitis
- Interventions
- Methoxsalen, Infliximab, Vedolizumab
- Drug
- Lead sponsor
- Therakos LLC
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Graft Versus Host Disease
- Interventions
- stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis), etanercept, methoxsalen
- Procedure · Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Sezary Syndrome
- Interventions
- Extracorporeal photopheresis (ECP), Methoxsalen Injection
- Device · Drug
- Lead sponsor
- Oleg E. Akilov, MD, PhD
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Pittsburgh, Pennsylvania
- Conditions
- HIV Infections
- Interventions
- Methoxsalen
- Drug
- Lead sponsor
- Therakos
- Industry
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Morristown, New Jersey
- Conditions
- Rheumatoid Arthritis
- Interventions
- Methoxsalen, Extracorporeal Photopheresis
- Drug · Procedure
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 10
- States / cities
- Westminister, Maryland • Worchester, Massachusetts • Morristown, New Jersey + 7 more
- Conditions
- Steroid Refractory Acute Graft Versus Host Disease
- Interventions
- Methoxsalen, Extracorporeal Photopheresis (ECP)
- Drug · Procedure
- Lead sponsor
- Therakos, Inc., a Mallinckrodt Company
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 13 more
- Conditions
- Graft Versus Host Disease, Cancer, Stem Cell Transplantation
- Interventions
- Extracorporeal Photopheresis
- Procedure
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Prostate Cancer
- Interventions
- X-PACT
- Combination Product
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Chronic Graft vs. Host Disease, Graft vs Host Disease, Graft-Versus-Host Disease
- Interventions
- Extracorporeal Photopheresis (ECP), Methoxsalen
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Stem Cell Leukemia of Unclear Lineage, Graft Versus Host Disease
- Interventions
- extracorporeal photopheresis
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Cutaneous T Cell Lymphoma, Mycosis Fungoides
- Interventions
- UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system
- Drug · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- ECP Methoxsalen, Standard of Care
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 11
- States / cities
- Miami, Florida • Indianapolis, Indiana • New Orleans, Louisiana + 7 more
- Conditions
- Graft-versus-Host Disease
- Interventions
- Methoxsalen, Extracorporeal Photopheresis
- Drug · Procedure
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- Not listed
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Gainesville, Florida • Chicago, Illinois + 6 more
- Conditions
- Acute Graft-versus-Host Disease
- Interventions
- Methoxsalen+ECP, Methylprednisolone, Ecp
- Drug · Procedure
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Ann Arbor, Michigan • New York, New York + 2 more
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- Cyclosporine, Methotrexate, Photopheresis, Mycofenolate mofetil, Pentostatin, allogeneic bone marrow, peripheral blood stem cell, Total body irradiation
- Drug · Procedure · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2014
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
- Conditions
- Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Interventions
- Gemcitabine combined with nab-paclitaxel, Dose -mFOLFIRINOX, Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel, Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine, Drug: Dose -SM-88
- Drug
- Lead sponsor
- Pancreatic Cancer Action Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 25
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 18 more
- Conditions
- Crohn Disease
- Interventions
- UVADEX and UVAR XTS Photopheresis System
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma
- Interventions
- SM-88
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland • Hackensack, New Jersey
- Conditions
- Sarcoma, Ewing, Sarcoma
- Interventions
- Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)
- Drug
- Lead sponsor
- Sarcoma Oncology Research Center, LLC
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS)
- Interventions
- Extracorporeal Photopheresis (ECP), No intervention in the SOC / Retrospective Chart review.
- Combination Product · Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 18 more